The use of estradiol metered-dose transdermal spray in clinical practice

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10387154" target="_blank" >RIV/00216208:11130/18:10387154 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/18:10387154 RIV/75010330:_____/18:00012331

Výsledek na webu

<a href="https://doi.org/10.1080/13697137.2018.1504916" target="_blank" >https://doi.org/10.1080/13697137.2018.1504916</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/13697137.2018.1504916" target="_blank" >10.1080/13697137.2018.1504916</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The use of estradiol metered-dose transdermal spray in clinical practice

Popis výsledku v původním jazyce

Objective: The aim of this study was to evaluate the use of novel estradiol metered-dose transdermal spray (EMDTS) in the treatment of acute climacteric syndrome. Methods: A multicenter open-label trial was conducted with a 24-week intervention. EMDTS 1.53 mg was given to symptomatic menopausal women. The Menopause Rating Scale (MRS) was used to assess the climacteric syndrome severity. The Friedman non-parametric test and a post-hoc test with Bonferroni correction were used for statistical evaluation. Results: A total of 132 women were enrolled in 20 centers, of whom 123 (93.2%) completed the study. The average age of patients was 53.8 years (37-65 years). The study was discontinued by 6.8% of women. The patients were checked at the beginning of the study, and after 12 and 24 weeks. There was a statistically significant drop (p &lt; 0.001) in MRS values both after 12 and 24 weeks of therapy. The average MRS values improved by 66.2% between the first and the third visits. The most significant improvement was manifested in patients with initial moderate climacteric syndrome (70.9%). Conclusion: This study confirms that application of EMDTS offers a novel treatment option for climacteric symptoms.

Název v anglickém jazyce

The use of estradiol metered-dose transdermal spray in clinical practice

Popis výsledku anglicky

Objective: The aim of this study was to evaluate the use of novel estradiol metered-dose transdermal spray (EMDTS) in the treatment of acute climacteric syndrome. Methods: A multicenter open-label trial was conducted with a 24-week intervention. EMDTS 1.53 mg was given to symptomatic menopausal women. The Menopause Rating Scale (MRS) was used to assess the climacteric syndrome severity. The Friedman non-parametric test and a post-hoc test with Bonferroni correction were used for statistical evaluation. Results: A total of 132 women were enrolled in 20 centers, of whom 123 (93.2%) completed the study. The average age of patients was 53.8 years (37-65 years). The study was discontinued by 6.8% of women. The patients were checked at the beginning of the study, and after 12 and 24 weeks. There was a statistically significant drop (p &lt; 0.001) in MRS values both after 12 and 24 weeks of therapy. The average MRS values improved by 66.2% between the first and the third visits. The most significant improvement was manifested in patients with initial moderate climacteric syndrome (70.9%). Conclusion: This study confirms that application of EMDTS offers a novel treatment option for climacteric symptoms.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Climacteric

ISSN

1369-7137

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

5

Strana od-do

549-553

Kód UT WoS článku

000453060600007

EID výsledku v databázi Scopus

2-s2.0-85054560339